Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors

Core Viewpoint - Unicycive Therapeutics, Inc. is facing a class action lawsuit due to a significant stock price drop following a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for a treatment related to chronic kidney disease [1][3]. Group 1: Legal Action - The Portnoy Law Firm is advising Unicycive investors to join a class action lawsuit for those who purchased securities between March 29, 2024, and June 27, 2025 [1]. - Investors have until October 14, 2025, to file a lead plaintiff motion [1]. Group 2: Stock Performance - Following the FDA's issuance of a CRL on June 30, 2025, Unicycive's stock price fell by $2.03 per share, representing a 29.85% decrease, closing at $4.77 per share [3]. Group 3: FDA Response - The FDA's CRL was issued due to deficiencies found in a third-party manufacturing vendor during a cGMP inspection, which was part of the NDA review process [3]. Group 4: Firm's Background - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].